Photo of Irving D. Kaplan,  MD

Irving D. Kaplan, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 632-8502
Fax: (617) 632-0339

Irving D. Kaplan, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Radiation Oncology, Harvard Medical School
  • Staff Radiation Therapist, Radiation Therapy, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

Research interests are primarily in the areas of prostate and lung cancer. Development of image guided radiation therapy both for external beam and brachytherapy for prostate cancer. Interests include hyperthermia and chemical radiation modifiers. Molecular predictors of tumor response. Development of combined modality therapy for the treatment of lung cancer.

Publications

Powered by Harvard Catalyst
  • Sun MR, Brook A, Powell MF, Kaliannan K, Wagner AA, Kaplan ID, Pedrosa I. Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors. AJR Am J Roentgenol 2016; 206:544-53. PubMed
  • Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA, . Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 2015; 116:179-84. PubMed
  • Buch K, Morancy T, Kaplan I, Qureshi MM, Hirsch AE, Rofksy NM, Holupka E, Oismueller R, Hawliczek R, Helbich TH, Bloch BN. Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance imaging: a feasibility study. J Contemp Brachytherapy 2015; 6:337-43. PubMed
  • Brenner MJ, Kaplan ID. Is there any benefit from hypofractionation in external-beam irradiation for prostate cancer? J Clin Oncol 2014. PubMed
  • Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract 2014; 10:107-12. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw 2013; 11:1364-72. PubMed
  • Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM, . Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys 2013. PubMed
  • Bubley GJ, Bloch BN, Vazquez C, Genega E, Holupka E, Rofsky N, Kaplan I. Accuracy of endorectal magnetic resonance/transrectal ultrasound fusion for detection of prostate cancer during brachytherapy. Urology 2013. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012; 30:3071-6. PubMed
  • Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola J, Wang Q, Bornstein BA, Hynynen K, Kaplan ID. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153. Cancer 2010. PubMed
  • Sanda MG,Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 2009; 301:2141-51. PubMed
  • Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - Pathogenesis and analysis of 673 cases. Oral Oncol 2008; 44:743-52. PubMed
  • Lu XQ, Shanmugham LN, Mahadevan A, Nedea E, Stevenson MA, Kaplan I, Wong ET, La Rosa S, Wang F, Berman SM. Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2008; 71:281-9. PubMed
  • Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250-61. PubMed
  • Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 2007; 110:2210-7. PubMed
  • Petit JH, Gluck C, Kiger WS 3rd, Laury Henry D, Karasiewicz C, Talcott JA, Berg S, Holupka EJ, Kaplan ID. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. Brachytherapy 2007; 6:267-71. PubMed
  • Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA 2006; 296:2316-7. PubMed
  • Kaplan ID, Meskell P, Oldenburg NE, Saltzman B, Kearney GP, Holupka EJ. Real-time computed tomography dosimetry during ultrasound-guided brachytherapy for prostate cancer. Brachytherapy 2006; 5:147-51. PubMed
  • Petit JH, Gluck C, Kiger WS 3rd, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity. Urol Oncol 2008; 26:372-7. PubMed
Hide